New COPD licence for Fostair

Fostair (formoterol/beclometasone) can now be prescribed for the symptomatic treatment of patients with severe COPD (FEV1 <50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.

Fostair (formoterol/beclometasone) delivers extra-fine particles allowing for a lower daily dose of corticosteroid
Fostair (formoterol/beclometasone) delivers extra-fine particles allowing for a lower daily dose of corticosteroid
The effect of formoterol/beclometasone on lung function and rate of exacerbation in patients with severe COPD (FEV1 30% to <50% predicted normal) was evaluated in two 48-week phase III studies.1

In the first, double-blind study (n=1186, analysis population), patients were randomised to receive formoterol/beclometasone (total daily dose 24/400 microgram) or formoterol alone (total daily dose 24 microgram).

A significant improvement in lung function (as assessed by change in pre-dose morning FEV1 from baseline to week 12) was observed for formoterol/beclometasone compared with formoterol alone (adjusted mean difference 0.07 [95% CI 0.04-0.10], p<0.001).2

Formoterol/beclometasone  also reduced the mean number of exacerbations per patient per year by 28% compared with formoterol alone (0.81 versus 1.11, adjusted rate ratio 0.72 [95% CI 0.62-0.84), p<0.001).2

In the second, three-arm parallel group study, 718 patients were randomised to receive treatment with formoterol/beclometasone metered dose inhaler (total daily dose 24/400 microgram), formoterol/budesonide dry powder inhaler (total daily dose 24/800 microgram) or formoterol dry powder inhaler (total daily dose 24 microgram).3

Formoterol/beclometasone was shown to be superior to formoterol alone (p=0.046) and non-inferior to formoterol/budesonide in terms of change in pre-dose morning FEV1 from baseline to 48 weeks.3

The mean rate of COPD exacerbations per patient per year was similar and did not differ significantly between the three treatment groups. All treatments were well tolerated.3

  1. Fostair Summary of Product Characteristics, March 2014.
  2. Agusti A et al. Poster presented at the European Respiratory Society Annual Congress. Barcelona, Spain, September 2013.
  3. Calverley PMA et al. Resp Med 2010; 104: 1858–68.

View Fostair drug record

Further information: Chiesi Ltd

Follow MIMS on Twitter

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases